1. Conference. NC. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.

2. Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am 1995;22(4):699-709.

3. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994;151(1):54-61.

4. Dean RC, Lue TF. Physiology of penile erection and pathophysiology of erectile dysfunction. Urol Clin North Am. 2005 Nov;32(4):379-95

5. Banya Y UT, Takagane H, et al. Two circulatory routes within the human corpus cavernosum penis: a scanning electron microscopic study of corrosion casts. Journal of Urology 1989;142:879-883.

6. Fournier GR, Jr., Juenemann KP, Lue TF, Tanagho EA. Mechanisms of venous occlusion during canine penile erection: an anatomic demonstration. J Urol 1987;137(1):163-7.

7. TF L. Hemodynamics of erection. Baltimore: Williams & Wilkins; 1988.

8. WH M. Sex after sixty five. Reflections 1977:31-43.

9. Rowland DL, Greenleaf W, Mas M, Myers L, Davidson JM. Penile and finger sensory thresholds in young, aging, and diabetic males. Arch Sex Behav 1989;18(1):1-12.

10. Christ GJ, Maayani S, Valcic M, Melman A. Pharmacological studies of human erectile tissue: characteristics of spontaneous contractions and alterations in alpha-adrenoceptor responsiveness with age and disease in isolated tissues. Br J Pharmacol 1990;101(2):375-81.

11. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Impotence and aging: clinical and hormonal factors. J Am Geriatr Soc 1988;36(6):511-9.

12. Seftel AD, Vaziri ND, Ni Z, Razmjouei K, Fogarty J, Hampel N, et al. Advanced glycation end products in human penis: elevation in diabetic tissue, site of deposition, and possible effect through iNOS or eNOS. Urology 1997. 50(6): 1016-26.

13. Angulo J, Cuevas P, Fernandez A, Gabancho S, Allona A, Martin-Morales A, et al. Diabetes impairs endothelium-dependent relaxation of human penile vascular tissues mediated by NO and EDHF. Biochem Biophys Res Commun 2003. 312(4): 1202-8.

14. Cartledge JJ, Eardley I, Morrison JF. Advanced glycation end-products are responsible for the impairment of corpus cavernosal smooth muscle relaxation seen in diabetes. BJU Int 2001. 87(4): 402-7.

15. Saenz de Tejada I, Goldstein I, Azadzoi K, Krane RJ, Cohen RA. Impaired neurogenic and endothelium-mediated relaxation of penile smooth muscle from diabetic men with impotence. N Engl J Med 1989. 320(16): 1025-30.

16. Nogues MA, Starkstein S, Davalos M, Berthier M, Leiguarda R, Garcia H. Cardiovascular reflexes and pudendal evoked responses in chronic haemodialysis patients. Funct Neurol 1991;6(4):359-65.

17. Shabsigh R, Klein LT, Seidman S, Kaplan SA, Lehrhoff BJ, Ritter JS. Increased incidence of depressive symptoms in men with erectile dysfunction. Urology 1998;52(5):848-52.

18. Araujo AB DR, Feldman HA, Goldstein I, McKinlay JB. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med 1998;60:458-465.

19. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983;12(1):59-66.

20. Angulo J, Cuevas P, Gabancho S, Gonzalez-Corrochano R, Videla S, Saenz de Tejada I. Enhancement of both EDHF and NO/cGMP pathways is necessary to reverse erectile dysfunction in diabetic rats. J Sex Med 2005. 2(3): 341-6.

21. Bancroft J, Wu FC. Changes in erectile responsiveness during androgen replacement therapy. Arch Sex Behav 1983. 12(1): 59-66.

22. Levine FJ GA, Goldstein I. Arteriographically determined occlusive disease within the hypogastric- cavernous bed in impotent patients following blunt perineal and pelvic trauma. Journal of Urology 1990;144:1147-1153.

23. Rosen MP, Greenfield AJ, Walker TG, Grant P, Dubrow J, Bettmann MA, et al. Cigarette smoking: an independent risk factor for atherosclerosis in the hypogastric-cavernous arterial bed of men with arteriogenic impotence. J Urol 1991;145(4):759-63.

24. Hsieh JT MS LT. influence of blood flow and blood pressure on penile erection. International Journal of Impotence Research 1989:35-42.

25. Rajfer J, Rosciszewski A, Mehringer M. Prevalence of corporeal venous leakage in impotent men. J Urol 1988;140(1):69-71.

26. Shiri, R., J. Koskimaki, J. Hakkinen, A. Auvinen, T.L. TammelaM. Hakama, Cardiovascular drug use and the incidence of erectile dysfunction. Int J Impot Res 2006.

27.Grimm, R.H., Jr., G.A. Grandits, R.J. Prineas, R.H. McDonald, C.E. Lewis, J.M. Flack, et al., Long-term effects on sexual function of five antihypertensive drugs and nutritional hygienic treatment in hypertensive men and women. Treatment of Mild Hypertension Study (TOMHS). Hypertension 1997. 29(1 Pt 1): 8-14.

28.Papatsoris, A.G.P.G. Korantzopoulos, Hypertension, antihypertensive therapy, and erectile dysfunction. Angiology 2006. 57(1): 47-52.

29.Chang, S.W., R. Fine, D. Siegel, M. Chesney, D. BlackS.B. Hulley, The impact of diuretic therapy on reported sexual function. Arch Intern Med 1991. 151(12): 2402-8.

30. Wolfe MM. Impotence on cimetidine treatment. N Engl J Med 1979;300(2):94.

31. Juenemann KP, Lue TF, Luo JA, Benowitz NL, Abozeid M, Tanagho EA. The effect of cigarette smoking on penile erection. J Urol 1987;138(2):438-41.

32. Miller NS, Gold MS. The human sexual response and alcohol and drugs. J Subst Abuse Treat 1988;5(3):171-7.

33. Morales A, Johnston B, Heaton JW, Clark A. Oral androgens in the treatment of hypogonadal impotent men. J Urol 1994;152(4):1115-8.

34. Arver S, Dobs AS, Meikle AW, Allen RP, Sanders SW, Mazer NA. Improvement of sexual function in testosterone deficient men treated for 1 year with a permeation enhanced testosterone transdermal system. J Urol 1996;155(5):1604-8.

35. Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH. Diagnostic evaluation of the erectile function domain of the International Index of Erectile Function. Urology 1999;54(2):346-51.

36. Lue TF. Erectile dysfunction. N Engl J Med 2000;342(24):1802-13.

37. Morales A, Gingell C, Collins M, Wicker PA, Osterloh IH. Clinical safety of oral sildenafil citrate (VIAGRA) in the treatment of erectile dysfunction. Int J Impot Res 1998;10(2):69-73; discussion 73-4.

38. Zippe CD, Kedia AW, Kedia K, Nelson DR, Agarwal A. Treatment of erectile dysfunction after radical prostatectomy with sildenafil citrate (Viagra). Urology 1998;52(6):963-6.

39. Chen Q, Wang N, Yao F, Lu X. [Comparison of efficacy and safety of phosphodiesterase type 5 inhibitors in the treatment of erectile dysfunction]. Zhonghua Nan Ke Xue 2004;10(4):302-4.

40. Padma-Nathan H. Efficacy and tolerability of tadalafil, a novel phosphodiesterase 5 inhibitor, in treatment of erectile dysfunction. Am J Cardiol 2003;92(9A):19M-25M.

41. Muller JE, Mittleman A, Maclure M, Sherwood JB, Tofler GH. Triggering myocardial infarction by sexual activity. Low absolute risk and prevention by regular physical exertion. Determinants of Myocardial Infarction Onset Study Investigators. Jama 1996;275(18):1405-9.

42. Herrmann HC, Chang G, Klugherz BD, Mahoney PD. Hemodynamic effects of sildenafil in men with severe coronary artery disease. N Engl J Med 2000;342(22):1622-6.

43. Cheitlin MD HA, Jr., Brindis RG, et al. ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol 1999;33:273-282.

44. Cheitlin MD HA, Jr., Brindis RG, et al. Use of sildenafil (Viagra) in patients with cardiovascular disease. Technology and Practice Executive Committee. Circulation 1999;99:168-177.

45.Thomson, P.D.R., Physicians’desk reference. Montvale, NJ: Thomson PDR 2005.

46.Physicians' Desk Reference. 58 ed. 2004, Thomson PDR: Montvale, NJ. 2662-5.

47.Kloner, R.A., G. Jackson, J.T. Emmick, M.I. Mitchell, A. Bedding, M.R. Warner, et al., Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol 2004. 172(5 Pt 1): 1935-40.

48.Kloner, R.A., Pharmacology and drug interaction effects of the phosphodiesterase 5 inhibitors: focus on alpha-blocker interactions. Am J Cardiol 2005. 96(12B): 42M-46M.

49.Montague, D.K., J.P. Jarow, G.A. Broderick, R.R. Dmochowski, J.P. Heaton, T.F. Lue, et al., Chapter 1: The management of erectile dysfunction: an AUA update. J Urol 2005. 174(1): 230-9.

50.Lee AG, Newman NJ., Erectile dysfunction drugs and nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 2005, 140; 707-8.

51.Tomsak, R., PDE5 inhibitors and permanent visual loss. Int J Impot Res 2005. 17(6): 547-9.

52.Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. J Neuroophthalmol 1994, 14; 38-44.

53.Hattenhauer, M.G., J.A. Leavitt, D.O. Hodge, R. GrillD.T. Gray, Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol 1997. 123(1): 103-7.

54.Nagy, V., Z. Steiber, L. Takacs, G. Vereb, A. Berta, Z. Bereczky, et al., Trombophilic screening for nonarteritic anterior ischemic optic neuropathy. Graefes Arch Clin Exp Ophthalmol 2006. 244(1): 3-8.

55.Carson, C.C., A.L. Burnett, L.A. LevineA. Nehra, The efficacy of sildenafil citrate (Viagra) in clinical populations: an update. Urology 2002. 60(2 Suppl 2): 12-27.

56.van Ahlen, H., J. Zumbe, K. StauchH. Landen, The real-life safety and efficacy of vardenafil: an international post-marketing surveillance study--results from 29 358 German patients. J Int Med Res 2005. 33(3): 337-48.

57. Kloner RA, Brown M, Prisant LM, Collins M. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Sildenafil Study Group. Am J Hypertens 2001;14(1):70-3.

58. Seidman SN, Roose SP, Menza MA, Shabsigh R, Rosen RC. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry 2001;158(10):1623-30.

59. Blander DS, Sanchez-Ortiz RF, Wein AJ, Broderick GA. Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res 2000;12(3):165-8.

60. Rendell MS, Rajfer J, Wicker PA, Smith MD. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. Jama 1999;281(5):421-6.

61. Wagner G, Montorsi F, Auerbach S, Collins M. Sildenafil citrate (VIAGRA) improves erectile function in elderly patients with erectile dysfunction: a subgroup analysis. J Gerontol A Biol Sci Med Sci 2001;56(2):M113-9.

62. Goldstein I, Young, J.M., Fischer, J., et al. Vardenafil a new phosphodiesterase type 5 inhibitor in the treatment of erectile dysfunction in men with diabetes: a multicenter double bline placebo controlled fixed dose study. Diabetes Care 2003;26:777-783.

63.Fisher, W.A., R.C. Rosen, M. Mollen, G. Brock, G. Karlin, P. Pommerville, et al., Improving the sexual quality of life of couples affected by erectile dysfunction: a double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005. 2(5): 699-708.

64.Montorsi, F., H. Padma-Nathan, J. Buvat, H. Schwaibold, M. Beneke, E. Ulbrich, et al., Earliest time to onset of action leading to successful intercourse with vardenafil determined in an at-home setting: a randomized, double-blind, placebo-controlled trial. J Sex Med 2004. 1(2): 168-78.

65. Young JM. Vardenafil. Expert Opin Investig Drugs 2002;11:1487-1496.

66. Sommer F, Engelmann, U. Vardenafil Bayer Yakuhin. Curr Opin Investig Drugs 2002;3:607-613.

67. Ormrod D, Easthope, S.E., Figgit, D.P. Vardenafil. Drugs Aging 2002;19:217-227.

68. Hellstrom, W.J., M. Gittelman, G. Karlin, T. Segerson, M. Thibonnier, T. Taylor, et al., Vardenafil for treatment of men with erectile dysfunction: efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002. 23(6): 763-71.

69. Padma-Nathan H, McMurray, J.G., Pullman, W.E., et al. On demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. International Journal of Impotence Research 2001;13:2-9.

70. Patterson B, Bedding, A., Jewell, H., et al. The effect of intrinsic and extrinsic factors on the pharmacokinetic properties of tadalafil (IC351). International Journal of Impotence Research 2001;13 (supplement 4):A120.

71. Brock, G.B., C.G. McMahon, K.K. Chen, T. Costigan, W. Shen, V. Watkins, et al., Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 2002. 168(4 Pt 1): 1332-6.

72.Sadovsky, R., T. Miller, M. MoskowitzG. Hackett, Three-year update of sildenafil citrate (Viagra) efficacy and safety. Int J Clin Pract 2001. 55(2): 115-28.

73.Padma-nathan, H., I. Eardley, R.A. Kloner, A.M. LatiesF. Montorsi, A 4-year update on the safety of sildenafil citrate (Viagra). Urology 2002. 60(2 Suppl 2): 67-90.

74.Morganroth, J., B.E. Ilson, B.C. Shaddinger, G.A. Dabiri, B.R. Patel, D.A. Boyle, et al., Evaluation of vardenafil and sildenafil on cardiac repolarization. Am J Cardiol 2004. 93(11): 1378-83, A6.

74.1. Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med 2000. 109 Suppl 9A: 3S-12S; discussion 29S-30S.

74.2.Hatzichristou D, Moysidis K, Apostolidis A, Bekos A, Tzortzis V, Hatzimouratidis K, et al. Sildenafil failures may be due to inadequate patient instructions and follow-up: a study on 100 non-responders. Eur Urol 2005. 47(4): 518-22; discussion 522-3.

74.3.Forgue ST, Patterson BE, Bedding AW, Payne CD, Phillips DL, Wrishko RE, et al. Tadalafil pharmacokinetics in healthy subjects. Br J Clin Pharmacol 2006. 61(3): 280-8.

74.4.Rajagopalan P, Mazzu A, Xia C, Dawkins R, Sundaresan P. Effect of high-fat breakfast and moderate-fat evening meal on the pharmacokinetics of vardenafil, an oral phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction. J Clin Pharmacol 2003. 43(3): 260-7.

74.5.Shabsigh R, Kaufman JM, Steidle C, Padma-Nathan H. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol 2004. 172(2): 658-63.

74.6.Musicki B, Champion HC, Becker RE, Liu T, Kramer MF, Burnett AL. Erection capability is potentiated by long-term sildenafil treatment: role of blood flow-induced endothelial nitric-oxide synthase phosphorylation. Mol Pharmacol 2005. 68(1): 226-32.

74.7..Musicki B, Champion HC, Becker RE, Kramer MF, Liu T, Sezen SF, et al. In vivo analysis of chronic phosphodiesterase-5 inhibition with sildenafil in penile erectile tissues: no tachyphylaxis effect. J Urol 2005. 174(4 Pt 1): 1493-6.

75. Ernst E, Pittler MH. Yohimbine for erectile dysfunction: a systematic review and meta-analysis of randomized clinical trials. J Urol 1998;159(2):433-6.

76. Gwinup G. Oral phentolamine in nonspecific erectile insufficiency. Ann Intern Med 1988;109(2):162-3.

77. Zorgniotti AW. Experience with buccal phentolamine mesylate for impotence. Int J Impot Res 1994;6(1):37-41.

78. Heaton JP, Morales A, Adams MA, Johnston B, el-Rashidy R. Recovery of erectile function by the oral administration of apomorphine. Urology 1995;45(2):200-6.

79. Rosen, R.C., L.E. Diamond, D.C. Earle, A.M. ShadiackP.B. Molinoff, Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141, a melanocortin receptor agonist, in healthy male subjects and in patients with an inadequate response to Viagra. Int J Impot Res 2004. 16(2): 135-42.

80.Diamond, L.E., D.C. Earle, R.C. Rosen, M.S. WillettP.B. Molinoff, Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. Int J Impot Res 2004. 16(1): 51-9.

81. Porst H. The rationale for prostaglandin E1 in erectile failure: a survey of worldwide experience. J Urol 1996;155(3):802-15.

82. Werthman P RJ. MUSE therapy: preliminary clinical observations. Urology 1997;50:809-811.

83. Padma-Nathan H, Hellstrom WJ, Kaiser FE, Labasky RF, Lue TF, Nolten WE, et al. Treatment of men with erectile dysfunction with transurethral alprostadil. Medicated Urethral System for Erection (MUSE) Study Group. N Engl J Med 1997;336(1):1-7.

84. Williams G, Abbou CC, Amar ET, Desvaux P, Flam TA, Lycklama a Nijeholt GA, et al. Efficacy and safety of transurethral alprostadil therapy in men with erectile dysfunction. MUSE Study Group. Br J Urol 1998;81(6):889-94.

85. RW L. Transurethral alprostadil with MUSE (medicated urethral system for erection) vs intracavernous alprostadil--a comparative study in 103 patients with erectile dysfunction. International Journal of Impotence Research 1998;10:61-62.

86. Linet OI, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Investig 1994;72(2):139-49.

87. Canale D, Giorgi PM, Lencioni R, Morelli G, Gasperi M, Macchia E. Long-term intracavernous self-injection with prostaglandin E1 for the treatment of erectile dysfunction. Int J Androl 1996;19(1):28-32.

88. Chew KK, Stuckey BG, Earle CM, Dhaliwal SS, Keogh EJ. Penile fibrosis in intracavernosal prostaglandin E1 injection therapy for erectile dysfunction. Int J Impot Res 1997;9(4):225-9; discussion 229-30.

89. Jeremy JY, Ballard SA, Naylor AM, Miller MA, Angelini GD. Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro. Br J Urol 1997;79(6):958-63.

90. Stief CG, Wetterauer U. Erectile responses to intracavernous papaverine and phentolamine: comparison of single and combined delivery. J Urol 1988;140(6):1415-6.

91. Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am 1995;22(4):833-45.

92. Kiely EA, Bloom SR, Williams G. Penile response to intracavernosal vasoactive intestinal polypeptide alone and in combination with other vasoactive agents. Br J Urol 1989;64(2):191-4.

93. Dinsmore WW, Alderdice DK. Vasoactive intestinal polypeptide and phentolamine mesylate administered by autoinjector in the treatment of patients with erectile dysfunction resistant to other intracavernosal agents. Br J Urol 1998;81(3):437-40.

94. Zaher TF. Papaverine plus prostaglandin E1 versus prostaglandin E1 alone for intracorporeal injection therapy. Int Urol Nephrol 1998;30(2):193-6.

95. Mirone V, Imbimbo C, Fabrizio F, Longo N, Palmieri A. Ketanserin plus prostaglandin E1 (PGE-1) as intracavernosal therapy for patients with erectile dysfunction unresponsive to PGE-1 alone. Br J Urol 1996;77(5):736-9.

96. Meinhardt W, de la Fuente RB, Lycklama a Nijeholt AA, Vermeij P, Zwartendijk J. Prostaglandin E1 with phentolamine for the treatment of erectile dysfunction. Int J Impot Res 1996;8(1):5-7.

97. Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol 1991;146(6):1564-5.

98. Weiss JN, Badlani GH, Ravalli R, Brettschneider N. Reasons for high drop-out rate with self-injection therapy for impotence. Int J Impot Res 1994;6(3):171-4.

99. Gupta R, Kirschen J, Barrow RC, 2nd, Eid JF. Predictors of success and risk factors for attrition in the use of intracavernous injection. J Urol 1997;157(5):1681-6.

100. Gomaa A, Shalaby M, Osman M, Eissa M, Eizat A, Mahmoud M, et al. Topical treatment of erectile dysfunction: randomised double blind placebo controlled trial of cream containing aminophylline, isosorbide dinitrate, and co-dergocrine mesylate. Bmj 1996;312(7045):1512-5.

101. JS W. Ligation of the dorsal vein of the penis as a cure for atonic impotence. Texas Med J 1902;18:325-327.

102. Kim ED, McVary KT. Long-term results with penile vein ligation for venogenic impotence. J Urol 1995;153(3 Pt 1):655-8.

103. Goodwin WE, Scardino PL, Scott WW. Penile prosthesis for impotence: case report. J Urol 1981;126(3):409.

104. Scott FB, Bradley, W.E., Timm, G.W. Management of erectile impotence . Use of implantable inflatable prosthesis. Urology 1973;2:80-82.

105. Small MP, Carrion HM, Gordon JA. Small-Carrion penile prosthesis. New implant for management of impotence. Urology 1975;5(4):479-86.

106. Michal V, Kramar R, Pospichal J, Hejhal L. [Direct arterial anastomosis on corpora cavernosa penis in the therapy of erective impotence]. Rozhl Chir 1973;52(9):587-90.

107. Michal V, Kramar R, Pospichal J. Femoro-pudendal by-pass, internal iliac thromboendarterectomy and direct arterial anastomosis to the cavernous body in the treatment of erectile impotence. Bull Soc Int Chir 1974;33(4):343-50.

108. Lue TF, Mueller SC, Jow YR, Hwang TI. Functional evaluation of penile arteries with duplex ultrasound in vasodilator-induced erection. Urol Clin North Am 1989;16(4):799-807.

109. Hauri D. Penile revascularization surgery in erectile dysfunction. Andrologia 1999;31 Suppl 1:65-76.

110. Virag R, Zwang G, Dermange H, Legman M, Penven JP. [Investigation and surgical treatment of vasculogenic impotency (author's transl)]. J Mal Vasc 1980;5(3):205-9.

111. Goldstein I. Overview of types and results of vascular surgical procedures for impotence. Cardiovasc Intervent Radiol 1988;11(4):240-4.

112. Breza J, Aboseif SR, Lue TF, Tanagho EA. Cavernous vein arterialization for vasculogenic impotence. An animal model. Urology 1990;35(6):513-8.

113. Zumbe J, Drawz G, Wiedemann A, Grozinger K, Engelmann U. Indications for penile revascularization and long-term results. Andrologia 1999;31 Suppl 1:83-7.

114. Sarramon JP, Bertrand N, Malavaud B, Rischmann P. Microrevascularisation of the penis in vascular impotence. Int J Impot Res 1997;9(3):127-33.

115. Goldstein I. Arterial revascularization procedures. Semin Urol 1986;4(4):252-8.

116. Lund GO, Winfield HN, Donovan JF. Laparoscopically assisted penile revascularization for vasculogenic impotence. J Urol 1995;153(6):1923-6.

117. Manning M, Junemann KP, Scheepe JR, Braun P, Krautschick A, Alken P. Long-term followup and selection criteria for penile revascularization in erectile failure. J Urol 1998;160(5):1680-4.

118. Benson CB, Vickers MA. Sexual impotence caused by vascular disease: diagnosis with duplex sonography. AJR Am J Roentgenol 1989;153(6):1149-53.

119. Fitzgerald SW, Erickson SJ, Foley WD, Lipchik EO, Lawson TL. Color Doppler sonography in the evaluation of erectile dysfunction: patterns of temporal response to papaverine. AJR Am J Roentgenol 1991;157(2):331-6.

120. Rudnick J, Bodecker R, Weidner W. Significance of the intracavernosal pharmacological injection test, pharmacocavernosography, artificial erection and cavernosometry in the diagnosis of venous leakage. Urol Int 1991;46(4):338-43.

121. Puyau FA, Lewis RW. Corpus cavernosography. Pressure flow and radiography. Invest Radiol 1983;18(6):517-22.

122. Wespes E, Delcour C, Struyven J, Schulman CC. Pharmacocavernometry-cavernography in impotence. Br J Urol 1986;58(4):429-33.

123. Delcour C, Wespes E, Vandenbosch G, Schulman CC, Struyven J. Impotence: evaluation with cavernosography. Radiology 1986;161(3):803-6.

124. Nehra A, Goldstein I, Pabby A, Nugent M, Huang YH, de las Morenas A, et al. Mechanisms of venous leakage: a prospective clinicopathological correlation of corporeal function and structure. J Urol 1996;156(4):1320-9.

125. Hatzichristou DG, Saenz de Tejada I, Kupferman S, Namburi S, Pescatori ES, Udelson D, et al. In vivo assessment of trabecular smooth muscle tone, its application in pharmaco-cavernosometry and analysis of intracavernous pressure determinants. J Urol 1995;153(4):1126-35.

126. Virag R, Saltiel H, Floresco J, Shoukry K, Dufour B. [Surgical treatment of vascular impotence by arterialization of the dorsal vein of the penis. Experience of 292 cases]. Chirurgie 1988;114(9):703-14.

127. Virag R, Bennett AH. Arterial and venous surgery for vasculogenic impotence: a combined French and American experience. Arch Ital Urol Nefrol Androl 1991;63(1):95-100.

128. Lue TF. Penile venous surgery. Urol Clin North Am 1989;16(3):607-11.

129. Lue TF. Penile venous surgery: factors affecting outcome. Abstracts for 66th annual meeting of western section AUA 1990;117.

130. Motiwala HG, Patel DD, Joshi SP, Baxi HM, Desai KD, Shah KN. Experience with penile venous surgery. Urol Int 1993;51(1):9-14.

131. Akoz, T., E. Kargi, M.R. KapucuB. Erdogan, The use of iliac bone flap as a penile stiffener in a diabetic patient with erectile dysfunction. Plast Reconstr Surg 1999. 103(7): 1975-8.

132.Mulcahy, J.J., E. Austoni, J.H. Barada, H.K. Choi, W.J. Hellstrom, S. Krishnamurti, et al., The penile implant for erectile dysfunction. J Sex Med 2004. 1(1): 98-109.

133.Levine, L.A.R.J. Dimitriou, Vacuum constriction and external erection devices in erectile dysfunction. Urol Clin North Am 2001. 28(2): 335-41, ix-x.

134.Montorsi, F., P. Rigatti, G. Carmignani, C. Corbu, B. Campo, G. Ordesi, et al., AMS three-piece inflatable implants for erectile dysfunction: a long-term multi-institutional study in 200 consecutive patients. Eur Urol 2000. 37(1): 50-5.

135.Bishop, J.R., J.W. Moul, S.A. Sihelnik, D.S. Peppas, T.S. GormleyD.G. McLeod, Use of glycosylated hemoglobin to identify diabetics at high risk for penile periprosthetic infections. J Urol 1992. 147(2): 386-8.

136.McMurray, J.G., R.A. Feldman, S.M. Auerbach, H. deRiesthalN. Wilson, Long-term effectiveness and tolerability of Viagra® (sildenafil citrate) in men with erectile dysfunction. Int J Impot Res 2002. 14(suppl 3): S104.

137.Cakan, M., F. Demirel, O. Karabacak, F. YalcinkayaU. Altug, Risk factors for penile prosthetic infection. Int Urol Nephrol 2003. 35(2): 209-13.